Aurinia Pharmaceuticals Total Assets 2011-2026 | AUPH

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Aurinia Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
752 M	551 M	548 M	471 M	543 M	464 M	327 M	146 M	190 M	57 M	33.6 M	52.4 M	23.1 M	4.16 M	14.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
752 M	4.16 M	278 M

Quarterly Total Assets Aurinia Pharmaceuticals

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
528 M	503 M	551 M	549 M	524 M	517 M	548 M	555 M	549 M	452 M	471 M	488 M	-	507 M	543 M	360 M	386 M	417 M	464 M	464 M	464 M	464 M	324 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
555 M	324 M	483 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Apellis Pharmaceuticals APLS	1.08 B	$ 20.41	-1.4 %	$ 2.57 B	USA
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	16.1 M	$ 0.79	-6.51 %	$ 4.31 M	China
Axsome Therapeutics AXSM	690 M	$ 165.07	-0.79 %	$ 8.21 B	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
AbCellera Biologics ABCL	1.36 B	$ 3.76	-1.7 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Burford Capital Limited BUR	3.11 B	$ 8.57	-1.83 %	$ 1.4 B	Britain
Corvus Pharmaceuticals CRVS	45.6 M	$ 18.11	1.23 %	$ 870 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	58.7 M	$ 26.36	-1.82 %	$ 706 M	USA
Certara CERT	1.56 B	$ 7.24	2.62 %	$ 1.16 B	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	149 M	$ 1.01	-0.98 %	$ 74.1 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Catalyst Pharmaceuticals CPRX	1.1 B	$ 23.77	-0.46 %	$ 2.91 B	USA
Agenus AGEN	314 M	$ 3.27	-2.09 %	$ 1.17 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.3 B	$ 28.85	-1.2 %	$ 1.67 B	USA
Champions Oncology CSBR	32.3 M	$ 5.98	-1.48 %	$ 81.7 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Завод ДИОД DIOD	1.4 B	-	-	-	Russia
Фармсинтез LIFE	2.05 B	-	-	-	Russia
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Cellectis S.A. CLLS	384 M	$ 3.71	-2.43 %	$ 116 M	France
Alector ALEC	293 M	$ 2.13	-3.39 %	$ 219 M	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	62.2 M	-	10.36 %	$ 9.8 M	USA
Altimmune ALT	139 M	$ 4.22	1.32 %	$ 300 M	USA
Teligent, Inc. TLGT	87.8 M	-	-13.85 %	$ 16.1 M	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Viela Bio, Inc. VIE	423 M	-	-	$ 2.91 B	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Amarin Corporation plc AMRN	671 M	$ 14.3	2.66 %	$ 5.93 B	Irlanda
AbbVie ABBV	134 B	$ 233.44	-0.33 %	$ 413 B	USA